CN102068520B - Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN102068520B CN102068520B CN2010106147622A CN201010614762A CN102068520B CN 102068520 B CN102068520 B CN 102068520B CN 2010106147622 A CN2010106147622 A CN 2010106147622A CN 201010614762 A CN201010614762 A CN 201010614762A CN 102068520 B CN102068520 B CN 102068520B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- cerebral
- chinese medicine
- medicine composition
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases. The Chinese medicinal composition is prepared from the following raw materials in part by weight: 9 to 18 parts of szechuan lovage rhizome, 20 to 40 parts of ginkgo leaf and 18 to 30 parts of hawthorn leaf. The Chinese medicinal composition has the effects of promoting blood circulation and removing blood stasis, relieving turbidity and lowering fat and the like; and pharmacological experiments show that the Chinese medicinal composition has the obvious pharmacological effects of inhibiting platelet aggregation and thrombosis, lowering blood fat, preventing atherosclerosis, cerebral ischemia or myocardial ischemia, and the like, can be used for cerebral circulation insufficiency or the cerebral ischemia caused by cerebral atherosclerosis or thrombus, and can also be used for myocardial ischemic diseases caused by coronary atherosclerosis or thrombus. The Chinese medicinal composition has a good curative effect in clinic application.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine composition of treating cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology
Cardiovascular and cerebrovascular disease is the particularly healthy commonly encountered diseases of middle-aged and elderly people of a kind of serious threat mankind, has " sickness rate is high, mortality rate is high, disability rate is high, relapse rate is high, complication many ", the characteristics of " four is high by more than ".Cardiovascular and cerebrovascular disease mainly is 11 kinds of diseases such as hypertension, coronary heart disease, myocardial infarction, cerebral thrombosis, cerebral embolism and cerebral hemorrhage.It is caused by arteriosclerosis, hypertension, hyperlipidemia, hyperglycemia, high blood viscosity and microcirculation disturbance.The medicine of treatment cardiovascular and cerebrovascular vessel mainly contains two big types at present: one type is simple expansion blood vessel medicine, and long-term prescription can make blood vessel follow the string, and causes sclerosis of blood vessels, and the state of an illness is more serious, even the angiorrhexis threat to life; One type is fat melting thrombolytic class, excretes mainly through the medicine dissolution arteriosclerosis plaque, and with it.This type of medicine can't prevent that rubbish such as vascular lipids from depositing once more, forms new speckle, and dissolution velocity is lower than deposition velocity, and the patient can only take medicine throughout the year.The patient that some are in a bad way, the support of being compelled to do, bridging, but tend to occur vascular restenosis, more inaccessible, damage phenomenon again.Although support, putting up a bridge temporarily tides over a critical period some patients with severe symptoms, patient's average mortality rises 13%～21.3% respectively in 5 years, and treatment costs an arm and a leg, and general family is difficult to accept.
Summary of the invention
The Chinese medicine composition that the purpose of this invention is to provide a kind of definite ingredients, quality controllable, safety good, purity is higher treatment cardiovascular and cerebrovascular disease.
Another object of the present invention provides the method for preparing of the Chinese medicine composition of above-mentioned treatment cardiovascular and cerebrovascular disease.
The Chinese medicine composition of treatment cardiovascular and cerebrovascular disease of the present invention is processed by the following weight parts proportion raw material: Rhizoma Chuanxiong 9～18, Folium Ginkgo 20～40, Folium Crataegi 18～30.
The weight portion proportion optimization of above-mentioned raw materials: Rhizoma Chuanxiong 12～16, Folium Ginkgo 25～35, Folium Crataegi 22～26.
Folium Ginkgo is the dried leaves of Ginkgoaceae plant Ginkgo biloba Ginkgo biloba L..Function with cure mainly: blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain is astringed the lung and is relievingd asthma, and changes turbid blood fat reducing; Be used for congestion resistance network, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, cough and asthma due to lung deficiency, hyperlipemia.The Folium Ginkgo main component is flavonoid glycoside and diterpenoid-lactone and organic acid.Folium Ginkgo mainly has the cerebral blood flow increasing amount, improves the brain cell metabolism, reduces cerebral vascular resistance, and the protection cerebral tissue reduces the brain tissue impairment that cerebral ischemia causes, and stablizes brain cell membrane, improves the many-sided effect of brain function.Very use it for the treatment cardiovascular and cerebrovascular disease both at home and abroad widely.
Folium Crataegi is the dried leaves of rosaceous plant Fructus Pyri Pashiae Cratagus pinnatifida Bge.var.majorN.E.Br. or Fructus Crataegi Cratagus pinnatifida Bge..Function with cure mainly: blood circulation promoting and blood stasis dispelling, regulate the flow of vital energy and promote blood circulation, change turbid blood fat reducing.Be used for qi depression to blood stasis, obstruction of qi in the chest and cardialgia, chest distress, palpitation and amnesia, vertigo and tinnitus, hyperlipemia.Research shows that the main active in the Folium Crataegi is a Folium Crataegi total flavones, mainly is Quercetin, rutin, hyperin, hypericin and vitexin etc.Modern pharmacological research shows that the flavone compound in the Folium Crataegi has blood pressure lowering, coronary blood flow increasing, blood fat reducing, triglyceride reducing and cholesterol, anoxia enduring, inhibition or removing oxygen-derived free radicals, anti peroxidation of lipid, improves effects such as liver microcirculation and anti-inflammatory damage, has bigger clinical value aspect cardio-cerebrovascular.
Rhizoma Chuanxiong is the dry rhizome of samphire Rhizoma Chuanxiong Ligusticum chuanxiong Hort..Function with cure mainly: blood-activating and qi-promoting, wind-expelling pain-stopping.Be used for obstruction of qi in the chest and cardialgia, the twinge of the breast side of body, tumbling and swelling, menoxenia, amenorrhea dysmenorrhoea ， mass in the abdomen stomachache, headache, rheumatic arthralgia.Modern study shows that effective ingredient ligustrazine and the ferulic acid of Rhizoma Chuanxiong etc. has the oxygen-derived free radicals of removing, calcium antagonism, expands multiple effects such as blood vessel, antiplatelet aggregation and thrombosis.
The method for preparing of the Chinese medicine composition of above-mentioned treatment cardiovascular and cerebrovascular disease may further comprise the steps:
(1) get the Rhizoma Chuanxiong decoction pieces, adding 8～14 times of amount volume ratios is 60%～90% alcohol reflux 1～2 hour, extracts 1～3 time, collects ethanol liquid, and decompression recycling ethanol is to there not being the extractum that alcohol is distinguished the flavor of;
(2) with the thick paste of Rhizoma Chuanxiong extracting solution simmer down to relative density 1.20～1.30 (50 ℃); Adding volume ratio and be 70%～90% ethanol is 40%～60% precipitate with ethanol to containing the alcohol amount, gets the supernatant decompression recycling ethanol after 12～36 hours, adds adjuvant; Drying gets extract A;
(3) get Folium Ginkgo, Folium Crataegi medicinal material coarse powder, add 6～10 times of amount volume ratios and be 60%～90% alcohol reflux or be heated to 60～75 ℃ and extracted 1～2 hour, extracts 2～3 times, collect ethanol extract, decompression recycling ethanol is to there not being the concentrated solution that alcohol is distinguished the flavor of;
(4) Folium Ginkgo, Folium Crataegi concentrated solution are dissolved in water to every ml soln contain crude drug 0.15～0.30g, cross macroporous resin adsorption, first water eccysis is assorted; The volume ratio that 3～6 times of cylinders of reuse are heavy is 30%～80% ethanol elution; Collect ethanol elution, decompression recycling ethanol concentrates; Vacuum drying gets extract B;
(5) extract A and extract B are mixed, the adding pharmacy can be accepted adjuvant and process preparation.
It is mannitol, microcrystalline Cellulose, starch, lactose, dextrin, polyvinylpyrrolidone, Tween 80, calcium phosphate, Polyethylene Glycol, silicon dioxide or magnesium stearate that above-mentioned pharmacy can be accepted adjuvant.
Above-mentioned preparation is tablet, capsule, granule, oral liquid, drop pill, patch or pill.
The present invention write out a prescription ratio optimization and effect conclusive evidence research
The present invention forms tool eleminating phlegm and freeing channels, promoting the circulation of QI to relieve pain effect by Folium Ginkgo, Folium Crataegi and Rhizoma Chuanxiong three flavor medical materials.Be used for having a headache due to the venation block, stagger, susceptible to lose temper due to restlessness, insomnia and dreamful sleep, chronic insufficient cerebral blood supply, arteriosclerosis, ischemia apoplexy and coronary heart disease.The clinician can adjust the prescription usage ratio because of patient's different phase state of an illness; Be scientific and reasonable more definite optimal proportion; Curing mainly test intended according to function adopts chmice acute cerebral ischemia, antithrombotic formation and normal pressure hypoxia endurance test to carry out the screening of best prescription proportioning; It is active to observe the different prescription ratios of the present invention, in the hope of obtaining optimal proportion.And can cross cerebral ischemic model, myocardial infarction and ischemia model and related pathologies test and further confirm pharmacological action.
One, test material
1. reagent medicine and instrument apparatus
1.1 receive the reagent thing: extract of the present invention, the inventor provides, lot number: 20091201,20091202 to 20091209; Tablet of the present invention, lot number 20100322,0.36g/ sheet (being equivalent to the 2.33g crude drug).Eleminating phlegm and freeing channels, promoting the circulation of QI to relieve pain.Be used for having a headache due to the venation block, stagger, susceptible to lose temper due to restlessness, insomnia and dreamful sleep, chronic blood supply insufficiency, cerebral arteriosclerosis and ischemia apoplexy, myocardial ischemia.Three times on the one, once two (being equivalent to the 5g crude drug approximately).Folium Ginkgo extract, specification: every gram extract is equivalent to the 23.2g crude drug, lot number: 20091201Y; Folium Crataegi extract, specification: every gram extract is equivalent to the 17.0g crude drug, lot number: 20091201S extracts preparation by the inventor according to same process.
1.2 positive control medicine
1.2.1 HUATUO ZAIZAO WAN: Qixing Pharmaceutical Co., Ltd., Guangzhou produces, lot number: 9146.Main component has Rhizoma Chuanxiong, Fructus Evodiae, Borneolum Syntheticum etc.Function: blood circulation promoting and blood stasis dispelling, eleminating phlegm and freeing channels, promoting the circulation of QI to relieve pain.The stroke in convalescent stage and the sequela that are used for phlegm stagnation in collateral, disease are seen hemiplegia, contracture numbness, facial hemiparalysis, slurred speech.Clinical consumption is 8g/ time, and 2 times/day, 30 days is a course of treatment.
1.2.2 Aspirin Enteric-coated Tablets: Bayer HealthCare Co, product batch number: BTA7WH3.
1.3 main agents
Chloral hydrate, Chemical Reagent Co., Ltd., Sinopharm Group; ADP, Switzerland Luo Shi (packing); Sodium citrate Guangzhou Qi Yun Bioisystech Co., Ltd; Picric acid, Guangzhou Chemical Reagent Factory.
1.4 instrument and apparatus
QX-200 whole blood platelet aggregation instrument: Instrument Factory of Shanghai Medical Univ.; Glass capillary (internal diameter 1mm, diameter 100mm): Huaxi Medical Univ instrument building and repair plant; Electronic balance (Mettler Toledo): Switzerland mettler-toledo group company; Constant Temp. Oven, Changsha medical apparatus and instruments factory etc.
2. laboratory animal and raising condition
2.1 laboratory animal
Kunming mice, SPF level, body weight: 18～22g, male and female dual-purpose, the quality certification number: SCXK (Guangdong) 2008-0020.SPF level rat, credit number: SCXK (Guangdong) 2009-0011.Above animal is provided by Zhongshan University's Experimental Animal Center.
2.2 raising condition
Feeding and management: all laboratory animals are raised at the Experimental Animal Center SPF of Zhongshan University level Animal House, by special messenger's feeding and management, and 5 in mice, the every cage of rat.
Facility condition: animal housing's heating ventilation and air-conditioning equipment is good, and room temperature is controlled at 22～25 ℃, and relative humidity is 50～70%.Receptacle is regularly sterilized according to routine.
Feedstuff and drinking-water: animal edible standard recipe production permit feedstuff, drink through autoclaved distilled water.
Three, prescription proportioning screening test
(1) test and dosage design
The present invention is made up of Folium Ginkgo, Folium Crataegi and Rhizoma Chuanxiong three flavor medical materials, is scientific and reasonable more definite optimal proportion, cures mainly test intended according to function and adopts chmice acute cerebral ischemia, antithrombotic formation and normal pressure hypoxia endurance test to carry out the screening of best prescription proportioning.Test adopts orthogonal test that the ratio of three flavor medical materials is studied, and is 15g in daily crude drug amount, then the about 2.5g crude drug/kg of mice dose,equivalent.
Table 1 divides into groups and the dosage design
Table 2 prescription test dosage and grouping orthogonal design
(2) test method and result
1. to the influence of mice normal pressure anoxia enduring
88 of method Kunming mouses, body weight 18～22g is divided into 11 groups at random, 8 every group.Receive the reagent group to be respectively the present invention and write out a prescription 1 to prescription 9, dosage is 2.5g crude drug/kg, positive drug HUATUO ZAIZAO WAN 2.1g/kg; Matched group waits the distilled water of capacity.The oral administration gavage administration, the administration volume: the 0.2ml/10g mice, totally 3 times, every day 1 time, 30min covers the bottle stopper that scribbles vaseline by only mice being put into the anoxia bottle that capacity is 250ml after the last administration, causes the seal anoxia.Write down the airtight bottleneck time; Constantly observe white mice respiratory frequency, the degree of depth, skin and lip change in color; Cease breathing up to animal, write down the death time, from covering bottle stopper to the time-to-live of breathless persistent period of animal as mice under the anoxia condition.
The result shows to observing the normal pressure hypoxia-bearing capability behind each 9 of mouse gavagings of group prescription comparative drug and the HUATUO ZAIZAO WAN three times that by table 3 result of the test raising is in various degree all arranged; Wherein with write out a prescription 3 with the positive control effect the most obvious, have significant difference (p＜0.05).
Each prescription of table 3 is to the influence (n=8,
) of mice normal pressure hypoxia endurance time
Annotate: compare * P＜0.05 with matched group
2. the influence of chmice acute cerebral anoxia
110 of method Kunming mouses, body weight 18～22g is divided into 11 groups at random, 10 every group.Receive the reagent group to be respectively the present invention and write out a prescription 1 to prescription 9, dosage is 2.5g crude drug/kg, positive drug HUATUO ZAIZAO WAN 2.1g/kg; Matched group waits the distilled water of capacity.The oral administration gavage administration, every day 1 time, totally 3 times, 30min by only breaking end, to dehisce breathes dwell time and dehisce number of times as anoxia enduring index after breaking end by stopwatch record mice immediately with mice after the last administration.
The result shows to each group mouse gavaging 9 prescription not have obviously and influence than behind medicine and the HUATUO ZAIZAO WAN three times acute brain being lacked mouse breathing time number average by table 4 result of the test; All prolong breathing time in various degree except that prescription 1 and prescription 9 are, but wherein write out a prescription 2, prescription 6, write out a prescription 7 and the breathing time (p＜0.05) of HUATUO ZAIZAO WAN significant prolongation mice.
Each prescription of table 4 is to the influence (n=9,
) of chmice acute cerebral anoxia
Annotate: compare * P＜0.05 with matched group
3. to the thrombotic influence of mice
110 of method Kunming mouses, body weight 18～22g is divided into 11 groups at random, 10 every group.Receive the reagent group to be respectively the present invention and write out a prescription 1 to prescription 9, dosage is 2.5g crude drug/kg, positive drug HUATUO ZAIZAO WAN 2.1g/kg; Matched group waits the distilled water of capacity.The oral administration gavage administration; Every day 1 time, totally 3 times, 30min will be to the carrageenin solution of mouse tail subcutaneous injection 0.2ml/10g body weight 1.0% after the last administration; Respectively organize the situation of mice thrombosis behind the observation injection carrageenin duplicating model in the 72h; Calculate incidence of thrombus (the interior number of animals of Mus number/group * 100% of thrombosis takes place), measure the length that thrombosis Mus squirrel tail becomes thrombosis takes place, calculate the percentage ratio that thrombosis length accounts for whole Mus tail.
The result is shown to blank group mice 100% behind the mouse subcutaneous injection carrageenin by table 5 result of the test and thrombosis occurs; To behind the medicine of each group mouse gavaging 9 prescription ratio or the aspirin three times except that prescription 2, prescription 5 and write out a prescription 7 all to the thrombosis inhibition not obvious outside; Prescription 4, prescription 8, prescription 9 and aspirin group modeling type 48h, 72h can significantly prolong and suppress thrombosis (p＜0.05), and prescription 3 and prescription 4 also can obviously suppress the formation of thrombosis.
Each prescription of table 4 is to the influence (n=10,
) of chmice acute cerebral anoxia
Annotate: compare * P＜0.05 with matched group
(3) test result analysis
To the medicine of 9 kinds of prescription ratios compositions, adopt chmice acute cerebral ischemia, normal pressure anoxia enduring and three tests of antithrombotic formation, result of the test is carried out weighted scoring and definite best comparison of the comprehensive analysis of single test result.The result can know by table 5 orthogonal test analysis, and chmice acute cerebral anoxia, normal pressure anoxia enduring and the best proportioning of three result of the test intuitive analysiss of antithrombotic shape are respectively A
2B
2C
3, A
1B
3C
3, A
3B
3C
1, Folium Ginkgo ratio increase curative effect not necessarily strengthens in the prompting prescription, and the Folium Crataegi recipe quantity increases curative effect and also increases, and is the positive dependency, and the amount of locating of Rhizoma Chuanxiong does not have clear and definite dependency with curative effect.By the best proportioning of three test weighted scorings intuitive analysis is A
2B
3C
1, C1 representes that Rhizoma Chuanxiong place amount is 1g, medical drugs custom in not meeting, The results of analysis of variance show the quantitative changeization of locating of three flavor medical materials all not have significance difference unusual, get C2, so the value proportion optimization of writing out a prescription is A
2B
3C
2, i.e. Folium Ginkgo 6g, Folium Crataegi 5g, Rhizoma Chuanxiong 3g.
The analysis of table 5 orthogonal experiments
Three, best prescription proportioning curative effect checking
According to definite ratio, by preparation technology of the present invention, the preparation test specimen is further through pharmacological testing checking curative effect.
1. to the influence of mice normal pressure anoxia enduring
70 of method Kunming mouses, body weight 18～22g is divided into 7 groups at random, 10 every group.Receive reagent group Folium Ginkgo extract 4.0g/kg respectively, Folium Crataegi extract 4.0g/kg is 1.94g/kg of the present invention, 3.88g/kg, 5.80g/kg, positive drug HUATUO ZAIZAO WAN 2.1g/kg; The blank group waits the distilled water of capacity.The oral administration gavage administration, administration volume 0.2ml/10g mice, every day 1 time, totally 3 times, 30min covers the bottle stopper that scribbles vaseline by only mice being put into the anoxia bottle that capacity is 250ml after the last administration, causes the seal anoxia.Write down the airtight bottleneck time; Constantly observe white mice respiratory frequency, the degree of depth, skin and lip change in color; Cease breathing up to animal, write down the death time, from covering bottle stopper to the time-to-live of breathless persistent period of animal as mice under the anoxia condition.
Result of the test shows as a result; The present invention all has prolongation than matched group each dose groups mice time-to-live under the normobaric hypoxia condition; And be dosage correlation; Relatively there were significant differences (P＜0.05 or P＜0.01) greater than 1.94g/kg (preparation 0.2g/kg) and normal control group for dosage wherein of the present invention, and the also variant but dosage of positive drug is obviously greater than the present invention, and it is not obvious singly to give heavy dose of Folium Ginkgo or Folium Crataegi extract effect; Prompting the present invention can improve the hypoxia-bearing capability of mice, and effect obviously is better than the single medical material of equivalent.The result sees table 6.
The influence of table 6 pair mice normal pressure hypoxia endurance time (n=10,
)
| Group | Dosage (g/kg) | Hypoxia endurance time (min) |
| The normal control group | - | 29.30±5.50 |
| Folium Ginkgo extract | 4.00 | 32.97±4.04 |
| Folium Crataegi extract | 4.00 | 34.77±3.60 |
| The present invention | 1.94 | 34.92±4.08* |
| The present invention | 3.88 | 38.02±4.68** |
| The present invention | 5.80 | 35.27±4.13* |
| HUATUO ZAIZAO WAN | 2.10 | 36.86±4.51** |
Annotate: compare with the normal control group: * P＜0.05, * * P＜0.01
2. the influence of chmice acute cerebral anoxia of the present invention
70 of method Kunming mouses, body weight 18～22g is divided into 7 groups at random, 10 every group.。Receive reagent group Folium Ginkgo extract 4.0g/kg respectively, Folium Crataegi extract 4.0g/kg is 1.94g/kg of the present invention, 3.88g/kg, 5.80g/kg, positive drug HUATUO ZAIZAO WAN 2.1g/kg; Matched group waits the distilled water of capacity.The oral administration gavage administration, administration volume 0.2ml/10g mice, every day 1 time, totally 3 times, 30min by only breaking end, to dehisce breathes dwell time and dehisce number of times as anoxia enduring index after breaking end by stopwatch record mice immediately with mice after the last administration.
Result of the test shows as a result; All can prolong after each dose groups administration of the present invention mice dehisce number of times with pant the time, and be dosage correlation, 3.88g/kg wherein of the present invention, two dosage of 5.80g/kg, positive drug group, Folium Crataegi extract and normal control group relatively have (P＜0.05 or P＜0.01) significantly unusually; Prompting the present invention can pass through blood brain barrier; Improve the ability of the anti-acute anoxia of mouse brain, improve brain energy metabolism, and pharmacological action of the present invention obviously is better than single composition.The result sees table 7.
The influence of table 7 pair chmice acute cerebral anoxia (
n=10)
| Group | Dosage (/kg) | The number of times of dehiscing | (s) continuously pants the time |
| The normal control group | - | 7.33±2.90 | 19.67±1.83 |
| Folium Ginkgo extract | 4.00 | 7.50±2.11 | 20.78±1.61 |
| Folium Crataegi extract | 4.00 | 7.17±2.44 | 21.45±1.92* |
| The present invention | 1.94 | 7.25±2.22 | 21.05±2.45 |
| The present invention | 3.88 | 8.08±2.54* | 25.33±2.82** |
| The present invention | 5.80 | 7.56±2.51* | 22.97±2.64** |
| HUATUO ZAIZAO WAN | 2.10 | 7.62±2.37* | 23.12±1.97** |
Annotate: compare with the normal control group: * P＜0.05, * * P＜0.01
3. the present invention is to clotting time of mice and thrombotic influence
70 of method Kunming mouses, body weight 18-22g, the male and female dual-purpose is divided into 7 groups at random by body weight and sex, 10 every group.Receive reagent group Folium Ginkgo extract 4.0g/kg respectively, Folium Crataegi extract 4.0g/kg is 1.94g/kg of the present invention, 3.88g/kg, 5.80g/kg, positive drug HUATUO ZAIZAO WAN 2.1g/kg; Matched group waits the distilled water of capacity.The oral administration gavage administration, administration volume 0.2ml/10g mice, every day 1 time, totally 3 times, 30min gets blood with glass capillary from eyeball after the last administration, and every 15s blocks a joint capillary tube, occurs the time of clotting strands in the observed and recorded capillary tube, and this is clotting time.After eyeball was got blood, hemostasis at once was with 10% chloral hydrate intraperitoneal injection of anesthesia with glass capillary for mice; From postcava blood drawing 0.5ml, add 3.4% sodium citrate anticoagulant (blood is 9: 1 with the ratio of anticoagulant), measure the platelet aggregation degree with QX-200 whole blood platelet aggregation instrument (impedance method); Get the 0.5ml anticoagulated whole blood and add 0.5ml whole blood dilution buffer liquid, add test sample or distilled water contrast liquid 100ul again, 37 ℃ of incubation 5min; Add the nickel core and stir back insertion platinum electrode, start " stirring " " measurement " key, the zeroing calibration; Then, add people's derivant 2mmol/L ADP 5ul (final concentration 10nmol/L), simultaneously by " regularly " key; Maximum concentration class ohmic value during record 5min, and calculate and suppress to assemble percentage rate.
Anticoagulant result of the test as a result shows that 1.30g/kg of the present invention, 3.88g/kg, three dosage of 5.80g/kg and positive drug group and normal control group comparison clotting time obviously prolong (P＜0.05 or P＜0.01), and the result sees table 8.
The antiplatelet aggregation result of the test shows; Each group of the present invention all has the effect that reduces platelet aggregation; And be dosage correlation, wherein 1.94g/kg, 3.88g/kg, three dosage of 5.80g/kg and positive drug group and normal control group comparison clotting time obviously prolong (P＜0.01).Prompting the present invention has tangible function of promoting blood circulation to disperse blood clots, and pharmacological action of the present invention obviously is better than single composition.The result sees table 8 and table 9.
The influence of table 8 pair clotting time of mice (n=10,
)
| Group | Dosage (g/kg) | Clotting time (s) |
| The normal control group | - | 210.0±76.68 |
| Folium Ginkgo extract | 4.00 | 284.3±39.85* |
| Folium Crataegi extract | 4.00 | 269.8±43.87* |
| The present invention | 1.94 | 268.1±43.43 |
| The present invention | 3.88 | 303.0±41.04** |
| The present invention | 5.80 | 304.3±57.86** |
| Aspirin | 0.019 | 308.4±42.85** |
Annotate: compare with the normal control group: * P＜0.05, * *＜P0.01
Table 9 couple ADP induces the influence (n=10,
) of rat whole blood platelet aggregation
Annotate: compare with the normal control group: * P＜0.05, * * P＜0.01
5. to the influence of intraluminal middle cerebral artery occlusion in rats bolt collimation method focal cerebral ischemia (MCAO) damage model
Method
Male SD rat is got in grouping and administration; Be divided into 6 groups by the random packet principle, be respectively the low 0.5g/kg of sham operated rats (distilled water), model group (distilled water), the present invention), in (1.0g/kg), high (2.0g/kg) dose groups organize with HUATUO ZAIZAO WAN (1.0g/kg).
Medicine is mixed with corresponding concentration with distilled water, makes the administration volume be the 1ml/100g rat.Gastric infusion twice in advance, divided two days, and one day respectively once.0.5h gastric infusion 1 time again before the modeling; 4h rechallenge after the modeling.Model group and sham operated rats rat give distilled water, and administration time and volume are the same.
Modeling method with rat with 10% chloral hydrate 3.5ml/kg intraperitoneal injection of anesthesia, neck median incision, separation, ligation left carotid, external carotid artery, and separate wing frontal artery.Be equipped with line, far-end placement bulldog clamp at the internal carotid artery near-end, common carotid artery crotch otch inserts the 4-0 nylon wire; Its degree of depth is 17～20mm, and the bolt line gets into internal carotid artery, goes into cranium to anterior cerebral artery; All blood flows of blocking-up middle cerebral artery source, wound be with iodophor disinfection, skin suture.Steam again then and raise.Sham operated rats is except that plug wire not, and all the other steps are the same.All the other respectively organize rat by above-mentioned operation method modeling.
The standard that modeling is successful: get operation side brain small pieces for every and carry out TTC dyeing, the color person that bleaches is the model success; Obvious operation side (i.e. left side) Horner disease (left side blepharoptosis, enophthalmos,enophthalmus) and operation side (promptly) hemiplegia Signs (can not the full extension left fore, topple over to the left during walking or turn-take) be arranged behind the animal surgery.Confirm as last experimental subject according to can the survive rat of 24h of above-mentioned standard, and carry out behavioristics's scoring and fast broken end get brain.The unsuccessful person of postoperative death and modeling does not include experiment statistics in, replenishes animal at random and guarantees at least 10 every group.
Collection of specimens: anesthetized animal extracts postcava blood, with 3000 rev/mins after centrifugal 10 minutes, draws supernatant as test serum.Adopt head-breaking to put to death animal, get cerebral tissue behind the broken end immediately, separate and removal olfactory bulb, XIAONAO and low brain stem, keep the brain part.
Observation index
(1) behavioristics's scoring survival 24h rat is observed rat behavior and learns variation, carries out neurological's scoring.4 fens system standards of grading with reference to Zea Longa:
0 minute, impassivity damage symptom;
1 minute, can not full extension offside fore paw;
2 minutes, turn-take laterally;
3 minutes, topple over to offside;
4 minutes, can not spontaneously walk loss of consciousness.
(2) after brain water content was measured neurological's scoring, broken end was got the Mus brain fast.Get left side half brain latter half and divide the another name weight in wet base, put 120 ℃ of baking boxs and dry, calculate brain water content, brain water content (%)=(weight in wet base-dry weight)/weight in wet base * 100% by following formula to constant weight.
(3) 24h rat after the mensuration modeling of cerebral infarction scope is got full brain fast, removes olfactory bulb, XIAONAO and low brain stem, freezing 25 minutes.The coronal section of going is then got the middle a slice of brain, puts rapidly in 1% red tetrazolium (TTC), and lucifuge, 37 ℃ of temperature were incubated 20 minutes, whenever stirred once at a distance from 7～8min therebetween, and the dyeing back is fixed with 4% paraformaldehyde.Coloration result: normal structure takes on a red color, and damage infarction tissue is white in color.Take pictures the back with weight method calculating brain infarction area percentage ratio.
The result
(1) behavioristics's appraisal result
The result shows promptly have hemiplegia appearance symptom to occur after regaining consciousness through the rat anesthesia behind the cerebral infarction ischemia-reperfusion.Mainly show as in various degree the operation offside forelimb and receive, the shoulder inward turning, muscular tension reduces, and pushes away right shoulder to side shifting, and resistance reduces, and also occur ceaselessly turn-taking to a side, even toppling over or can not the autonomic activities phenomenon to offside appears in some animal.By table 10, compare with model group, the middle and high dosage of behavior scoring the present invention (1.0g/kg, the 2.0g/kg) group of postoperative 24h and positive drug HUATUO ZAIZAO WAN group all have behavioristics's scoring of obvious reduction MCAO rat, and there were significant differences for statistical analysis (P＜0.05).The general state of postoperative model group animal is relatively poor, the movable minimizing.
The table 10 pair ethological influence of MCAO rat nerves
Annotate: compare with model group: * P＜0.05, * * P＜0.01; Compare with sham-operation: ##P＜0.01
(2) to the influence of brain water content
The result shows that sham operated rats rat brain water content is lower, and the model group brain water content is significantly higher than sham operated rats; The middle and high dosage of the present invention (1.0g/kg, 2.0g/kg) group all significantly is lower than model control group (P＜0.01), and positive control HUATUO ZAIZAO WAN group also can significantly reduce brain water content (comparing P＜0.01 with model group)).The result sees table 11.
The influence
of table 11 pair MCAO rat brain water content
| Group | Dosage (mg/kg) | Number of animals (only) | Brain water content (%) |
| Sham operated rats | - | 10 | 77.9±1.24** |
| Model control group | - | 11 | 80.2±1.15 |
| Low dosage of the present invention | 0.5 | 10 | 79.4±1.30 |
| Dosage among the present invention | 2.0 | 10 | 78.6±0.87** |
| High dose of the present invention | 2.0 | 11 | 78.1±1.10** |
| The positive drug group | 1.0 | 10 | 78.5±0.95** |
Annotate: compare with model group: * P＜0.05, * * P＜0.01; Compare with sham-operation: ##P＜0.01
(3) to the influence of rat cerebral infarction scope
This experiment is that 24h utilizes TTC staining technique inspection cerebral infarction degree behind the cerebral infarction.Rat cerebral tissue's infraction degree is obvious behind the cerebral ischemia 24h, and infarct size accounts for 23.49 ± 4.36% of total brain area.After the present invention and the HUATUO ZAIZAO WAN administration, cerebral infarct size percentage ratio is obviously descended.The sham operated rats animal does not see that cerebral infarction takes place.The result sees table 12.
The influence
of table 12 pair MCAO rat cerebral infarction area
| Group | Dosage (mg/kg) | Number of animals (only) | Brain infarction area (%) |
| Sham operated rats | - | 10 | 0## |
| Model control group | - | 11 | 23.49±4.36 |
| Low dosage of the present invention | 250 | 10 | 19.81±7.47 |
| Dosage among the present invention | 500 | 10 | 18.37±3.94* |
| High dose of the present invention | 750 | 11 | 16.40±3.69** |
| The positive drug group | 1440 | 10 | 18.30±5.49** |
Annotate: compare with model group: * P＜0.05, * * P＜0.01; Compare with sham-operation: ##P＜0.01
The influence of myocardial ischemia due to the 6 pairs of rat coronary ligations
60 of method rats are divided into 6 groups at random; Every group 10; Male and female half and half are respectively sham operated rats (giving distilled water), negative control group (being model group) gives distilled water, the present invention low (0.5g/kg), in (1.0g/kg), high (2.0g/kg) dose groups and HUATUO ZAIZAO WAN (1.0g/kg).Continuous irrigation stomach 3 days is irritated behind the stomach 30min anesthesia (20% urethane 0.5ml/100g lumbar injection) last day and is fixed on the operation plate.Slotting trachea connects artificial respirator, and the sterilization of chest QUMAO along the about 2cm of midclavicular line longitudinal incision skin, separates the flesh layer in the 3rd or the 4th intercostal passivity, opens the thoracic cavity, cuts off pericardium, gently presses the right side thorax, extrudes heart.Behind ligation ramus descendens anterior arteriae coronariae sinistrae in coronary artery place between arterial cone and the left auricle, put back to the thoracic cavity to heart, sew up the thoracic cavity rapidly, stop the artificial respiration.The normal II lead electrocardiogram of a period of time, ligation branch of coronary artery were again traced in this experiment earlier before rat opens breast.Back electrocardiogram index (operation was controlled in 30 minutes) pricked in record.Following index is detected in the operation back.
Observation index
(1) Electrocardiographic variation: before the ligation with ligation after heart rate, J point displacement (mv) and the T wave amplitude (mv) of 60min.
(2) myocardial infarction area: put to death rat behind the 240min; Win heart; Put-20 ℃ of refrigerator and cooled and froze 30 minutes, laterally be cut into 5, put in the TTC liquid 37 ℃ of water bath heat preservations 15 minutes, the non-orchid of each sheet cardiac muscle is dyed district (infarct) cutting-out; Claim weight in wet base, calculating is myocardial infarct size (infarcted region/heart heavy * 100%) with the ratio of total heart weight.
The result
(1) influence Electrocardiographic to rats with myocardial ischemia
The myocardial ischemia change appears in animal very soon after opening breast knot bundle rat coronary artery anterior descending branch, and it is towering to show as ECG T wave, and the J point is raised, and changes basicly stable a level after one hour.Contrast with the distilled water group; Each dose groups of the present invention all has the ECG change of the myocardial ischemia due to the antagonism coronary ligation; Following table 13,14 visible the present invention's height, middle dose groups and HUATUO ZAIZAO WAN group can significantly stop the variation (P＜0.01) of coronary ligation rat electrocardiogram J point and T ripple, and low dosage of the present invention also shows and has certain effect.It is thus clear that the present invention has obvious protective effect to ligation property myocardial ischemia.The result sees table 13～15 for details.
The influence of rat electrocardio J point displacement (mv) changing value due to the table 13 pair ligation property myocardial ischemia (x ± SD)
With model group contrast, * P＜0.05, * * P＜0.01
The influence of rat electrocardio T ripple displacement (mv) changing value due to the table 14 pair ligation property myocardial ischemia (x ± SD)
With model group contrast, * P＜0.05, * * P＜0.01
The influence of rat electrocardio and heart rate changing value due to the table 15 pair ligation property myocardial ischemia (x ± SD)
With model group contrast, * P＜0.05, * * P＜0.01
(2) to the influence of myocardial infarct size
It is 20.17% that result of the test display model group myocardial infarction is enclosed, and administration is respectively organized infarction size and significantly reduced (P＜0.05 or P＜0.01).Show that the present invention has the effect of significantly dwindling myocardial infarct size, see simultaneously with the enhanced dose-effect relationship of dosage increase effect.Show that the present invention has the good protection effect to the coronary ligation rat.The result sees table 16.
The influence of table 16 pair rats with myocardial ischemia myocardial infarct size (X ± SD)
Compare * * P＜0.01 with model group
Above-mentioned experimental study result shows that the present invention's three flavor Chinese medicine Folium Ginkgos, Folium Crataegi and Rhizoma Chuanxiong three flavor quality of medicinal material ratios are that 6: 5: 3 curative effects are better; Processing finished tablet through preparation technology of the present invention gives rats with cerebral ischemia, rats with myocardial ischemia and related pathologies animal pattern and takes doses; The result further proves conclusively cerebral blood supply insufficiency or the cerebral ischemia diseases that the present invention causes cerebral atherosclerosis or thrombosis, and coronary atherosclerosis or thrombosis cause that diseases such as myocardial ischemia have better therapeutical effect.
The prescription of the Chinese medicine composition of treatment cardiovascular and cerebrovascular disease of the present invention is advanced, and method technology is simple, processing ease, and the Chinese medicine composition that is obtained has significant curative effect to cardiovascular and cerebrovascular disease.The present invention instructs meticulous prescription to form, and motherland's medical science is thought, the incidence and development of cardiovascular and cerebrovascular disease; Or because of deficiency in origin, or because of eating and drinking without temperance, or because of feelings will internal injury; So that function is not normal, to give birth in the blood stasis, the various clinical manifestations of cardiovascular and cerebrovascular disease appear; If the state of an illness can not be effectively controlled, will develop forming the resistance of venation numbness in this stage, critical illness such as apoplexy, heart infarction take place.The cardiovascular and cerebrovascular disease cause of disease is different, but its key link is " blood stasis ".Rhizoma Chuanxiong among the present invention, acrid in the mouth, warm in nature, return liver, gallbladder, pericardium channel, blood-activating and qi-promoting is arranged, the effect of wind-expelling pain-stopping, can blood circulation promoting and blood stasis dispelling to promote blood circulation, again can promoting qi circulation, resolving food retention with pain relieving, no matter the stagnation of QI, blood stasis pain all can be used, so be monarch drug; Folium Ginkgo sweet in the mouth, hardship, puckery, property is flat, and GUIXIN, lung meridian are astringed the lung and are relievingd asthma, and the effect of promoting blood circulation, removing blood stasis and relieving pain can be treated apoplexy or reached the thoracic obstruction; Folium Crataegi, blood circulation promoting and blood stasis dispelling is regulated the flow of vital energy and is promoted blood circulation, and changes turbid blood fat reducing, returns Liver Channel; Be used for qi depression to blood stasis, obstruction of qi in the chest and cardialgia, vertigo and tinnitus, hyperlipidemia; The cerebral arterial insufficiency person, Folium Ginkgo, Folium Crataegi are the medicine of blood circulation promoting and blood stasis dispelling, coronary circulation-promoting pain-relieving, are all ministerial drug, to help Rhizoma Chuanxiong blood stasis dispelling effect.The same usefulness of three medicines, function of promoting blood circulation to disperse blood clots strengthen, and can circulation of qi promoting, can invigorate blood circulation again, but also turbidity removal make the gas promoting the circulation of blood smooth, the pathogenesis of the cardiovascular and cerebrovascular disease that hits.Confirm that through clinical practice and pharmacological evaluation Chinese medicine composition effect of the present invention is obvious, determined curative effect, the headache and dizzy that particularly causes for old people's chronic insufficient cerebral blood supply.
The Chinese medicine composition of treatment cardiovascular and cerebrovascular disease of the present invention; Have the pharmaceutical purity height, evident in efficacy, and have that extraction ratio is high, drug loss is few; Advantage of simple technology; Use the effect with dosage Folium Ginkgo or Folium Crataegi to improve greatly than singly, it is evident in efficacy through pharmacodynamics test proof, is clinical a kind of better efficacy, convenient Chinese medicine composition and the preparation thereof of providing.
Concrete embodiment
Below in conjunction with illustrated embodiments the present invention is described further, but protection scope of the present invention is not limited in following examples.
Embodiment 1
Get Folium Ginkgo 1000g, Folium Crataegi 835g and Rhizoma Chuanxiong 500g, Folium Ginkgo, Folium Crataegi add 60% ethanol and are heated to 80 ℃ of extractions twice respectively, filter; Merging filtrate, decompression filtrate recycling ethanol is not to there being the alcohol flavor, and concentrated solution is dissolved in water; Leave standstill after-filtration, D101 macroporous resin on the filtrating is used 75% ethanol elution; Collect eluent, with the eluent decompression recycling ethanol, drying under reduced pressure obtains Folium Ginkgo, the dried cream of Folium Crataegi.Rhizoma Chuanxiong adds 80% ethanol reflux twice respectively, each 2 hours, filters merging filtrate; To there not being the alcohol flavor, precipitate with ethanol leaves standstill, and inclines to supernatant with decompression filtrate recycling ethanol; With the supernatant decompression recycling ethanol, add the dry microcrystalline Cellulose of adjuvant, obtain the dried cream of Rhizoma Chuanxiong.With adding microcrystalline Cellulose 50g, lactose 24g, starch 20g, magnesium stearate is an amount of, and evenly mixed, tabletting is processed 1000 in tablet.
Embodiment 2
Get Folium Ginkgo 900g, Folium Crataegi 885g and Rhizoma Chuanxiong 580g, Folium Ginkgo adds 70% ethanol and is heated to 60 ℃ of extractions twice respectively, filters; Merging filtrate, decompression filtrate recycling ethanol is not to there being the alcohol flavor, and concentrated solution is dissolved in water; Leave standstill after-filtration, FL-2 macroporous resin on the filtrating is used 85% ethanol elution; Collect eluent, with the eluent decompression recycling ethanol, drying under reduced pressure obtains the dried cream of Folium Ginkgo.Folium Crataegi adds 65% ethanol reflux, extract, twice respectively, filters merging filtrate; Decompression filtrate recycling ethanol is not to there being the alcohol flavor, and concentrated solution is dissolved in water, and leaves standstill after-filtration; ADS-17 macroporous resin on the filtrating is used 70% ethanol elution, collects eluent; With the eluent decompression recycling ethanol, drying under reduced pressure obtains the dried cream of Folium Crataegi.Rhizoma Chuanxiong adds 75% ethanol reflux twice respectively, and each 1.5 hours, filter, merging filtrate, to there not being the alcohol flavor, precipitate with ethanol leaves standstill, and inclines to supernatant with decompression filtrate recycling ethanol, and with the supernatant decompression recycling ethanol, drying under reduced pressure obtains the dried cream of Rhizoma Chuanxiong.Adding microcrystalline Cellulose 120g, lactose 30g, starch 20g, evenly mixed, with 95% medicinal alcohol system soft material, to cross 24 mesh sieves and granulate, drying is 4 hours under 60 ℃ of conditions, the granulate that sieves, film coating is processed 100 bags of granules.
Embodiment 3
Get Folium Ginkgo 750g, Folium Crataegi 725g and Rhizoma Chuanxiong 350g, Folium Ginkgo, Folium Crataegi add 70% ethanol and are heated to 75 ℃ of extractions twice, filter; Merging filtrate, decompression filtrate recycling ethanol is not to there being the alcohol flavor, and concentrated solution is dissolved in water; Leave standstill after-filtration, FL-2 macroporous resin on the filtrating is used 85% ethanol elution; Collect eluent, with the eluent decompression recycling ethanol, drying under reduced pressure obtains Folium Ginkgo, the dried cream of Folium Crataegi.Rhizoma Chuanxiong adds 70% ethanol reflux twice respectively, each 2 hours, filters merging filtrate; To there not being the alcohol flavor, precipitate with ethanol leaves standstill, and inclines to supernatant with decompression filtrate recycling ethanol; With the supernatant decompression recycling ethanol, add the microcrystalline Cellulose drying under reduced pressure, obtain the dried cream of Rhizoma Chuanxiong.Folium Ginkgo, the dried cream of Folium Crataegi and the dried cream of Rhizoma Chuanxiong are evenly mixed, add microcrystalline Cellulose 20g, starch 30g; Carboxymethyl starch sodium 10g, mix homogeneously is with 50% medicinal alcohol system soft material; Cross 24 mesh sieves and granulate, drying is 4 hours under 60 ℃ of conditions, 20 mesh sieve granulate; Add an amount of micropowder silica gel, filled capsules gets 500 of capsules.
Embodiment 4
Get Folium Ginkgo 950g, Folium Crataegi 880g and Rhizoma Chuanxiong 580g, Folium Ginkgo adds 70% ethanol and is heated to 60 ℃ of extractions twice respectively, filters; Merging filtrate, decompression filtrate recycling ethanol is not to there being the alcohol flavor, and concentrated solution is dissolved in water; Leave standstill after-filtration, D101 macroporous resin on the filtrating is used 80% ethanol elution; Collect eluent, with the eluent decompression recycling ethanol, drying under reduced pressure obtains the dried cream of Folium Ginkgo.Folium Crataegi adds 70% ethanol reflux, extract, twice respectively, filters merging filtrate; Decompression filtrate recycling ethanol is not to there being the alcohol flavor, and concentrated solution is dissolved in water, and leaves standstill after-filtration; ADS-17 macroporous resin on the filtrating is used 70% ethanol elution, collects eluent; With the eluent decompression recycling ethanol, drying under reduced pressure obtains the dried cream of Folium Crataegi.Rhizoma Chuanxiong adds 75% ethanol reflux twice respectively, each 2 hours, filters merging filtrate; To there not being the alcohol flavor, precipitate with ethanol leaves standstill, and inclines to supernatant with decompression filtrate recycling ethanol; With the supernatant decompression recycling ethanol, add the microcrystalline Cellulose drying under reduced pressure, obtain the dried cream of Rhizoma Chuanxiong.Three kinds of dried cream mix, and pulverize, and add dextrin 10g, microcrystalline Cellulose 15g, and briquetting, the pill bar, pill promptly gets pill 500 balls.
Clinical practice
Zhang, the woman 65 years old, rose before 2 years; Often no obvious inducement burst is dizzy, just like very dizzy, can not open order when serious, simultaneously with nausea and vomiting; Through all not obvious with the Chinese and western drugs therapeutic effect, the symptom intermittent attack, so that the daily life of can not taking care of oneself, walking step state is unstable.See dizziness and blurred vision at present, tinnitus, the tending to vomit of feeling sick, lip, purplish tongue are dark, white and thin fur, hesitant pulse.Show that as blood examination plasma viscosity, platelet gather and attach rate and be higher than normal value, cerebral blood flow diagram bilateral blood supply of vertebral artery is not enough, the no abnormal discovery of CT examination.Western medicine diagnose: the bilateral blood supply of vertebral artery is not enough, and tcm diagnosis: dizzy (stasis of blood hinders clear key) given the tablet of the embodiment of the invention 1 gained, and 2/inferior, 3 times/day, after 2 week, remission, dizzy attack times reduces, conscious condition improved.Fully recover behind the first quarter moon.Follow up a case by regular visits to half a year, dizzy not recurrence again.
Lee, woman, 60 years old.The patient had the coronary disease medical history 3 years. bring out angina pectoris when fatigue or the emotion of being everlasting is melancholy, and medicines such as clothes sorbitrate nitroglycerin, effect is not good enough.Examine and see: expression is painful, feeling of oppression and pain in the chest. dark complexion, dizzy cardiopalmus, dim, the white and thin fur of purplish tongue, stringy and hesitant pulse.The prompting of electrocardio circle: the S-T section obviously descends, and the T ripple is inverted. deficiency myocardial blood supply Western medicine diagnose: angina pectoris.Tcm diagnosis: the thoracic obstruction: card belongs to the heart arteries and veins stasis of blood and stagnates.Give the present invention, 2/inferior, 3 times/day, uncomfortable in chest after one month, chest pain alleviates, still dizzy cardiopalmus.Continue and give the present invention, 2/inferior, 3 times/day, pain uncomfortable in chest disappears after fortnight, the time had palpitation dizzy, continue to give the tablet of the embodiment of the invention 1 gained, 2/inferior, 3 times/day, all diseases are eliminated after 2 week, the electrocardiogram check recovers normal. follow up a case by regular visits to and do not see recurrence in 2 years.
The dragon certain, women, 60 years old.Year is interrupted at ordinary times and takes metoprolol surplus in the of dizzy 10, and blood pressure continues at 160/105mmHg, and nearly 2 weeks come because of anxious state of mind, dizzy aggravation, and blurred vision has uncomfortable in chest, cardio palmus concurrently.Do when dizzy at present, dizzy and flower is looked the thing rotation, chest distress and palpitation symptoms, and purplish tongue is dim, and petechia is arranged, white and thin fur, thready and hesitant pulse.Western medicine diagnose: hypertension (2 grades), tcm diagnosis: dizzy (stasis of blood hinders clear key).Give the tablet of the embodiment of the invention 1 gained, 2/inferior, 3 times/day, after 3 week, cardiopalmus fades, dizzy alleviating, and it is clear to look thing, and thing revolves and ends, uncomfortable in chest remaining unchanged, blood pressure 140/90mmHg, all diseases disappear.
Claims (7)
1. a Chinese medicine composition of treating cardiovascular and cerebrovascular disease is characterized in that, is processed by the following weight parts proportion raw material: Rhizoma Chuanxiong 9～18, Folium Ginkgo 20～40, Folium Crataegi 18～30.
2. the Chinese medicine composition of treatment cardiovascular and cerebrovascular disease according to claim 1 is characterized in that, the weight portion proportioning of each raw material is: Rhizoma Chuanxiong 12～16, Folium Ginkgo 25～35, Folium Crataegi 22～26.
3. the Chinese medicine composition of treatment cardiovascular and cerebrovascular disease according to claim 1 and 2 is characterized in that, the dosage form of said Chinese medicine composition is tablet, capsule, granule, oral liquid, drop pill, patch or pill.
4. the Chinese medicine composition of treatment cardiovascular and cerebrovascular disease according to claim 3; It is characterized in that said cardiovascular and cerebrovascular disease is meant that cerebral blood supply insufficiency that cerebral atherosclerosis or thrombosis cause or cerebral ischemia diseases and coronary atherosclerosis or thrombosis cause myocardial ischemia disease.
5. the method for preparing of the Chinese medicine composition of the described treatment cardiovascular and cerebrovascular disease of claim 1 is characterized in that, comprises the steps:
(1) get the Rhizoma Chuanxiong decoction pieces, adding 8～14 times of amount volume ratios is 60%～90% alcohol reflux 1～2 hour, extracts 1～3 time, collects ethanol liquid, and decompression recycling ethanol is to there not being the extractum that alcohol is distinguished the flavor of;
(2) with the thick paste of Rhizoma Chuanxiong extracting solution simmer down to relative density 1.20～1.30, adding volume ratio and be 70%～90% ethanol is 40%～60% precipitate with ethanol to containing the alcohol amount, gets the supernatant decompression recycling ethanol after 12～36 hours, adds adjuvant, drying, extract A;
(3) get Folium Ginkgo, Folium Crataegi medicinal material coarse powder, add 6～10 times of amount volume ratios and be 60%～90% alcohol reflux or be heated to 60～75 ℃ and extracted 1～2 hour, extracts 2～3 times, collect ethanol extract, decompression recycling ethanol is to there not being the concentrated solution that alcohol is distinguished the flavor of;
(4) Folium Ginkgo, Folium Crataegi concentrated solution are dissolved in water to every ml soln contain crude drug 0.15～0.30g, cross macroporous resin adsorption, first water eccysis is assorted; The volume ratio that 3～6 times of cylinders of reuse are heavy is 30%～80% ethanol elution; Collect ethanol elution, decompression recycling ethanol concentrates; Vacuum drying gets extract B;
(5) extract A and extract B are mixed, the adding pharmacy can be accepted adjuvant and process preparation.
6. the method for preparing of the Chinese medicine composition of treatment cardiovascular and cerebrovascular disease according to claim 5 is characterized in that, the model of said macroporous resin is D101, FL-2, ADS-17, D102, AB-8 or SA-1.
7. the method for preparing of the Chinese medicine composition of treatment cardiovascular and cerebrovascular disease according to claim 5; It is characterized in that it is mannitol, microcrystalline Cellulose, starch, lactose, dextrin, polyvinylpyrrolidone, Tween 80, calcium phosphate, Polyethylene Glycol, silicon dioxide or magnesium stearate that said pharmacy can be accepted adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106147622A CN102068520B (en) | 2010-12-30 | 2010-12-30 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106147622A CN102068520B (en) | 2010-12-30 | 2010-12-30 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102068520A CN102068520A (en) | 2011-05-25 |
| CN102068520B true CN102068520B (en) | 2012-07-25 |
Family
ID=44027398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106147622A Active CN102068520B (en) | 2010-12-30 | 2010-12-30 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102068520B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920806B (en) * | 2012-08-08 | 2014-11-26 | 山西康禾农业有限责任公司 | Nerve-soothing blood-pressure-reducing traditional Chinese medicine tea |
| CN102940702B (en) * | 2012-10-31 | 2014-05-28 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN103392873A (en) * | 2013-08-03 | 2013-11-20 | 北京绿源求证科技发展有限责任公司 | Food-grade health tea soluble granules capable of nourishing brain |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771988A (en) * | 2005-11-16 | 2006-05-17 | 张文芳 | Two-leaf composition for treating cardiac and cerebral vascular diseases |
| CN101293067A (en) * | 2008-05-29 | 2008-10-29 | 王跃进 | Capsule for coronary disease |
-
2010
- 2010-12-30 CN CN2010106147622A patent/CN102068520B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1771988A (en) * | 2005-11-16 | 2006-05-17 | 张文芳 | Two-leaf composition for treating cardiac and cerebral vascular diseases |
| CN101293067A (en) * | 2008-05-29 | 2008-10-29 | 王跃进 | Capsule for coronary disease |
Non-Patent Citations (1)
| Title |
|---|
| 陈开文.活血化瘀药物在心脑血管疾病治疗中的作用.《中国医药指南》.2010,第8卷(第15期),42－44. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102068520A (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524421B (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN100457176C (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
| CN102698137B (en) | Composition with blood pressure reducing function and preparation method of same | |
| CN103719493A (en) | Brain-boosting and intelligence-enhancing sealwort health-care tea and preparation method thereof | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107007689B (en) | A kind of Chinese medicine preparation of temperature compensation heart kidney and its production and use | |
| CN107441329A (en) | A kind of Chinese medicinal formulae nursed one's health for diabetes and Sjogren syndrome | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN106177712A (en) | A kind of magnificent Bulbus Allii bean treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN104998087A (en) | Traditional Chinese medicine composition for treating primary hypertension and preparing method of traditional Chinese medicine composition | |
| CN101129431A (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease and relative disease, method of preparing the same and application of the same | |
| CN100546637C (en) | A kind of Chinese medicine composition for the treatment of coronary heart disease and preparation method thereof | |
| CN104352866A (en) | Traditional Chinese medicine preparation for treating fire-toxin fluid-impairment type burns and preparation method thereof | |
| CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
| CN107913315A (en) | A kind of Chinese medicine composition for treating refractory hypertension and preparation method thereof | |
| CN108478701A (en) | A kind of lozenge of strengthen immunity | |
| CN103798475B (en) | Chinese herbal medicine honey tea (sugar-free particles) for improving sub-health status of perimenopause and preparation technology thereof | |
| CN116370556B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, tonifying qi and soothing nerves and preparation method thereof | |
| CN103520260B (en) | One treats treating coronary heart disease and angina pectoris combination and preparation method | |
| CN105664048A (en) | Pharmaceutical composition inhibiting gastric cancer cell proliferation and application thereof | |
| CN100443093C (en) | AIDS treating medicine | |
| CN106110089A (en) | A kind of Chinese medicine composition treating anxiety, insomnia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHOU QING |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20111031 Address after: 510635 Guangdong city of Guangzhou province Tianhe District Tianhe North Road, No. 609 Hua Hui Hua s Plaza Pavilion room 1707 Applicant after: GUANGZHOU BOJI MEDICAL BIOTECHNOLOGY Co.,Ltd. Address before: 510635 Guangdong city of Guangzhou province Tianhe District Tianhe North Road, No. 609 Hua Hui Hua s Plaza Pavilion room 1707 Applicant before: Guangzhou Boji Medical Biotechnology Co.,Ltd. Co-applicant before: Zhou Qing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 510670 Building 2, 3, 4 and 5, No. 62, Nanxiang 1st Road, Science City, Huangpu District, Guangzhou, Guangdong Province Patentee after: Boji Pharmaceutical Technology Co.,Ltd. Address before: 510635 Guangdong city of Guangzhou province Tianhe District Tianhe North Road, No. 609 Hua Hui Hua s Plaza Pavilion room 1707 Patentee before: GUANGZHOU BOJI MEDICAL BIOTECHNOLOGY Co.,Ltd. |